
November 2026
London, UK
Follow along live as industry leaders unveil the latest advancements in biomedicine.
15:05
Panel Discussion: NextGen Vaccine Strategies To Advance Cancer Treatment
Moderator: ANTONIO POSTIGO, Chief Scientific Officer, Stratosvir Ltd
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery
Moderator: STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, DMPK, GSK
Empowering Antibody Engineering – Highlights From Early Beginnings Of Using AI-Based Tools For Optimization & Functional Engineering Of Antibody Candidates
BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck
Panel Discussion: Mixed Modalities: Addressing The Challenges & Opportunities To Drug The Undruggable
Multivalent Ligand Design To Selectively Bind Proteins
NATHAN ALVES, Research Director, Indiana University School Of Medicine
15:30
Cyclotides As Ultra-Stable Combinatorial Display Platforms For Peptide-Based Drug Discovery
DAVID CRAIK, Professor, University Of Queensland
Enhancing Biologics Lead Optimisation By Combining Affinity Prediction Methods & Active Learning
OWEN VICKERY, Associate Principal Scientist, AstraZeneca
InSiDe Out: In Silico Developability Screening At AstraZeneca, Impact To Date & Future Direction
ISABELLE SERMADIRAS, Associate Principal Scientist, AstraZeneca
15:55
Unveiling Hidden Targets: AI-Driven Discovery Of Therapeutic Cancer Antigens From The Dark Genome
CHRISTIAN GARDE, Director, Evaxion
The Identification Of Cyclic Peptide Metabolic Soft Spots By Isotope-Labelled Reductive Dimethylation & Leveraging High-Resolution Ion Mobility-Mass Spectrometry
MARIA FAWAZ, Associate Principal Scientist, MS
Using The Very Small To Tackle The Very Large – Our Journey From Concept To Clinic
IJEOMA UCHEGBU, Professor Of Pharmaceutical Nanoscience, University College London
First-In-Class Site-Directed Targeted soloMER Drug Conjugate For Autoimmune Inflammation
OBINNA UBAH, Principal Scientist, Elasmogen
Rationalising MABs Developability Testing
DAVID BROCKWELL, Professor, University Of Leeds
16:20
Development & Qualification Of A Cell-Based Potency Assay For Two Novel DNA Cancer Vaccine
ELISA MARELLI, Research Scientist, Scancell
Short Novel Peptides As Chelating Agents For Metal-Related Diseases
MICHAL SHOSHAN, Founder & Chief Executive Officer, metaLead Therapeutic
Purification Of Oligonucleotides & Their Conjugates For Progressing Early Drug Discovery Projects & The Chromatographic Challenges With Oligonucleotide G-rich Sequences
YIPING WU, Senior Scientist, AstraZeneca
Removing Biological Roadblocks To Better Treatments: The Power Of Nanofitin-Enhanced Biologics
MATHIEU CINIER, Scientific Director, Affilogi
From beginning to end, NextGen Biomed showcased the remarkable innovation within our community.
The event featured engaging content and discussions across the entire value chain—from antibody engineering advancements to sustainable practices in TIDES chemistry—underscoring our collective commitment to advancing immunotherapy and biologics R&D.
Cell 2026
Welcome to Cell, Oxford Global’s flagship event, serving as the ultimate meeting place for bioprocessing and advanced therapy professionals. This event brings together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell & gene therapy value chain. In line with current industry trends, the event explores the transformative power of AI and machine learning in manufacturing, driving innovation and efficiency in advanced therapies.

Explore the Cell Programme
Key Themes
We asked key opinion leaders which breakthroughs will shape the future of advanced therapies. Automation is transforming manufacturing and analytics, making processes more efficient and scalable. At the same time, evolving regulations are working to keep pace, ensuring faster access for patients. AI/ML are driving smarter bioprocessing, while plug-and-play platforms are streamlining therapy development. In parallel, stem cell research is unlocking new possibilities in cancer treatment, and microRNA technologies are paving the way for precise gene regulation. With collaboration, innovation, and cutting-edge science, the field is advancing faster than ever. Now is the time to shape its future.
An unmissable journey awaits you: from award winning speakers and insightful workshops to an exclusive gala dinner. Discover the moments that will transform your Cell experience.
Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?
Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow, Lundbeck; Andrew Buchanan, Principal Scientist, AstraZeneca
Presentation: What Does The Future Hold For Orally Available Peptides?
Presented by: Immanuel Lerner, Chief Executive Officer,
Pepticom
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK
Panellists include
Saul Martinez Montero, Senior Director, RNA Therapeutics, Dyne Therapeutics
Morten Lindow, RNAHub Founder & Mission Lead, Roche
Sritama Bose, Head Of Chemistry Research & Innovation, NATA
Fazel Shabanpoor, Co-Founder & Chief Scientific Officer & Associate Professor & Head Of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches
Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna
Presentation: How Vaccines & Immunotherapy Strategies: Converging Pathways For Preventing Or Treating Chronic Diseases
Presented by: Daniel Larocque, Innovation Lead, Innovation & Emerging Science, Sanofi
Key Event Highlights
An unmissable journey awaits you: from celebrated keynote speakers and insightful fireside chats, to an exclusive gala dinner at London's Science Museum. Discover the moments that will transform your NextGen Biomed experience.
The start-up zone provides a unique opportunity to for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals.
It's designed for start-ups from across the cell & gene space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans.
For further information and to get started, submit the application form below.

Meet 2025's Expert Speakers
The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.
Advanced Therapies Specialist Team Leader,
Genscript
Biologics 2024 has been one of the best events I have attended so far in my career.
Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.
Impressed by the effort to bring people together.
Business Development Director,
Bioassay
Nice set-up, with good support for exhibitors
Director of Client Relations,
ImmunoPrecise
Interested in Sponsoring NextGen Biomed?
Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.
Who is Sponsoring Cell 2026?
Silver Sponsors
Bronze Sponsors
Network & Programme Sponsors
Sponsors of Cell 2025 included
At Advanced Instruments, now proudly part of Nova Biomedical, we’re entering a new chapter - combining powerful technologies to support your bioprocessing workflows from start to finish.
Our Solentim® Cell Line Development (CLD) solutions remain at the core of our offering for biotherapeutic developers. With industry-leading technology for single-cell deposition, high-resolution imaging, and smart clone selection, we help accelerate timelines and reduce risk in CLD workflows.
But our support doesn’t stop there. We also offer tools that ensure data quality and process reliability across the lab:
* OsmoTECH®: Bioprocessing osmometers for process development and QC * FLEX2: Cell culture analyzers for efficient process monitoring * Artel: Volume verification for pipettes and liquid handlers
We would love to meet during the event to explore how our solutions can support your CLD and bioprocessing goals.
Learn more about the merger: https://www.aicompanies.com/nova-merger/
Training Partner

Powering Go-To-Market For Life Science Teams
Succession helps founders and sales teams close more deals with biotech and pharma. We partner with our clients to run modern lead generation campaigns, up-skill their team through personalized sales training, and build AI workflows using cutting edge tools and technology.
Interested in Sponsoring Cell 2026?
Become a driving force in connecting leaders from every stage of the value chain to drive advanced therapy development & novel biologics processing. Cell 2026 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Unlock the Latest News and Insights
Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.
Register Now
Be part of the new wave of bioprocessing and advanced therapy innovation,
Partner with us
Become a driving force in accelerating the next generation of cell culture and cell & gene therapy to patients

.png)



